Objective-To assess the impact of the national breast cancer screening programme on breast cancer mortality in the first years after its introduction.
Nationwide breast screening programmes have been introduced since the late 1980s. Although their goal is reduction in breast cancer mortality, relatively few reports have yet been published on such reductions. [1] [2] [3] [4] Changes in breast cancer mortality related to early detection and treatment are expected to appear only several years after the introduction of a screening programme. In England and Wales, however, a decrease of 12% in the age standardised mortality in the age group 55-69 was already observed within seven years after the introduc-tion of the NHS breast screening programme. This fall in mortality was concluded to be only partially as a result of screening. 2 In Finland 4 a reduction in mortality of 24% was found in women aged 50-59 in the period 1987-92. However, this result was based on small numbers and was not statistically significant.
In the Netherlands the nationwide screening programme carried out at two-yearly intervals started around 1989. By the end of 1997 the target population of women was completely covered: all women aged 50-69 had been invited at least once. Before its introduction we predicted that the programme would yield a maximum annual mortality reduction of 17% in the total female population from the year 2015 onwards. 5 In the present study we analysed the breast cancer mortality in the first years after introduction of a screening programme in the Netherlands and United Kingdom, and investigated whether there was a decrease that might be attributed to the increased use of screening mammography. We used a validated model of breast cancer screening. 5 6 The expected figures for the Dutch programme were compared with the observed breast cancer mortality rates in the Netherlands in the period 1986-96.
Material and methods

THE MICROSIMULATION SCREENING ANALYSIS (MISCAN) APPROACH
In MISCAN a population is simulated according to the demographic characteristics of the population under study (births, life tables, deaths from causes other than breast cancer). The incidence and mortality of breast cancer of this population are reproduced. The natural history of breast cancer is modelled as a progression through successive disease states. Four invasive stages are distinguished according to tumour diameter-T1a, T1b, T1c, and T2+ (< 5, > 5-10, >10-20, and >20 mm)-and a proportion of the lesions is assumed to be preceded by a screen detectable ductal carcinoma in situ (dCIS). Without screening a screen detectable preclinical cancer may be diagnosed clinically or progress to the next preclinical invasive state. The time spent in each preclinical state, which is assumed to be exponentially distributed, and the rate at which preclinical cancers are clinically diagnosed is inferred from data on the clinical incidence and stage distribution before screening started, and on the detection rates and interval cancer rates by stage in the population concerned.
The stage-specific survival after clinical diagnosis without screening is based on data from survival registries.
The eVects of a screening programme are calculated by comparing the clinical incidence and mortality with and without screening. To simulate the clinical incidence and the mortality without screening, demographic and epidemiological characteristics of the population under study are implemented in the model. After adding the screening characteristics (screening ages, interval, and attendance) and the performance of the screening programme (determined by the sensitivity and specificity of the screening test and improvement in prognosis after screen detection) of the population under study to the model, the clinical incidence and mortality when screening is carried out are calculated. The sensitivity in the model is based on the results of the Dutch nationwide screening programme, 7 and for women aged over 50 it was fixed as 0.4, 0.65, 0.8, 0.9, and 0.95 for dCIS, T1a, T1b, T1c, and T2+ tumours respectively. Women with screen detected cancers are assumed to have a reduced risk of dying from breast cancer depending on the tumour size at detection. This improvement in prognosis (defined as 1 minus the ratio of the risk of dying of screen detected cancer divided by the risk when the cancer has been diagnosed in the absence of screening) was based on analyses of the five Swedish randomised trials 5 (see Appendix 1) .
As the output of the microsimulation model MISCAN is subject to random fluctuation we simulated a multiple of the population under study to minimise the model fluctuation, resulting in a standard deviation of the estimates that was five times smaller than in real life. A more detailed description of MISCAN is given elsewhere. 5 6 MORTALITY REDUCTION OF BREAST CANCER
AFTER THE INTRODUCTION OF SCREENING
The cancer mortality reduction after the introduction of screening was assessed by comparing the mortality with and without screening. Mortality reduction was calculated for both a MISCAN model incorporating Dutch demographic, epidemiological, and screen characteristics, 5 8 and for a model adjusted for the demographic, epidemiological, and screen characteristics in the UK 9 , assuming the North West health region to be representative of the United Kingdom. 10 The age distribution of the population was based on the European standard population 11 in both models. Important diVerences in screening performance between the two models are the duration of the preclinical phase for small tumours and the survival after clinical diagnosis. 9 The duration of the preclinical tumours up to 10 mm is assumed to be twice as long in the UK as in the Netherlands, which indicates a better detection of smaller tumours in the UK programme. Survival after clinical diagnosis is less favourable in the UK than in the Netherlands. In both models the gradual introduction of the screening programme was taken into account. In the Netherlands the programme was gradually introduced from 1989 to 1995, except for two pilot projects which started earlier. In the UK the separate screening programmes started between November 1987 and March 1993 Figure 1 Age standardised mortality rates, with and without screening, observed in the Netherlands and predicted by MISCAN, for the age groups 45-49, 50-59, 60-69, and 70-74. The expected mortality reduction for these age groups after five, 10, and 15 years of screening is also shown.
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Results
MORTALITY REDUCTION AFTER INTRODUCTION
OF THE DUTCH PROGRAMME Figure 1 shows the breast cancer mortality, with and without screening, predicted by MISCAN for the age groups 45-49, 50-59, 60-69, and 70-74 in the period 1989-2004, the first 15 years after the start of the screening programme, together with the observed breast cancer mortality in these age groups in the years 1989-96. 12 In the first years after the introduction of a screening programme little reduction in breast cancer mortality is expected: from 1989 to 1991 the expected mortality reduction was less than 1% for all ages. This is due to the time lag between early diagnosis and the eVect of this on mortality, and due to the gradual introduction of screening.
After that time the expected reduction in mortality increased continually. In 2004, the diVerence in the breast cancer mortality, with and without screening, is expected to increase to 18% in the 50-59 age group, 29% in the 60-69 age group, and 23% in the 70-74 age group.
The observed mortality rates during 1986-88, the period before screening started, compared well with expected mortality. After the introduction of screening in the years 1989-96, the expected mortality rates, with screening, compared well with the observed mortality rates, but observed mortality rates were also not statistically diVerent from the expected mortality, without screening, except for some peculiar fluctuations in the observed mortality rates. Table 1 shows that the observed mortality in 1996 was still not significantly diVerent from the observed mortality in 1986-88, before screening started. This result, however, was expected, because 1997 is the first year in which the expected probability of seeing a significant reduction is high enough to reach a power of 0.80.
The null hypothesis that the diVerence in the mortality in 1986-88 and a following year can be explained by random fluctuation will only be rejected with a probability of 80% if the mortality in that year is smaller than the mortality rate in 1986-88 minus 1.96 × (expected standard deviation of the diVerence in mortality under the null hypothesis) minus 0.84 × (expected standard deviation of the difference in mortality if the alternative hypothesis that mortality after 1988 is lower than the mortality before screening, is true). The mortality in a certain year must therefore be smaller than 105.2−1.96 × 3.2−0.84 × 3.1 = 96.3. The first year in which the mortality in the age group 55-74 is expected to be smaller than 96.3 is 1997. Therefore only from this year onwards is there a considerable probability that the reduction in mortality due to screening will be reflected in the mortality rates.
COMPARISON OF THE DUTCH AND NHS BREAST
SCREENING PROGRAMMES
In the NHS breast screening programme reduction in breast cancer mortality in the first years after the start of screening was predicted to be low. Figure 2 compares the expected mortality reduction of the NHS and Dutch nationwide screening programmes in the first 15 years of screening. We compared the mortality reduction in respectively the 20-year and 15-year age group (in accordance with the target age ranges of the Dutch and NHS programmes respectively) with the highest mortailty reduction, the age group 55−74 in the Netherlands to the age group 55−69 in the UK. After a short period in which the expected mortality reduction was higher for the Dutch screening programme because of two pilot projects which started earlier, the expected reduction in breast cancer mortality was higher for the UK programme until 10 years after the introduction of screening. This was due to the faster implementation of the screening programme in the UK. After that, the eVects of the Dutch screening programme are expected to be higher, because of the shorter screening interval in the Netherlands (two years v three years). In the long term the Dutch nationwide screening programme is predicted to produce a 29% mortality reduction for the age group 55-74, while the maximum mortality reduction of the NHS breast screening programme is predicted to be 24% in the age group 55-69. (UK 1988 -2003 , the Netherlands 1989 -2004 
Figure 2 Expected reduction in breast cancer mortality after the introduction of screening
Discussion
According to the MISCAN breast cancer model the reduction in breast cancer mortality due to the nationwide screening programme in the Netherlands is expected to be low in the first years after the introduction of screening. These slight changes cannot be seen in the observed breast cancer mortality rates owing to the random fluctuation of mortality rates. It is expected that from 1997 onwards breast cancer mortality in the Netherlands will diVer significantly from the mortality before screening in the age group 55-74; it will take longer to establish the eVect of screening for the five year age groups. Swedish 1 and Australian 13 analyses have also shown the need for a long follow up to estimate the eVects of screening on mortality.
One of the key variables aVecting the prediction of mortality reduction due to screening is the improvement in prognosis after screen detection, which is an extrapolation of the results of the Swedish randomised trials. This should be noted carefully, by comparing predicted and observed breast cancer mortality, if it is valid to assume that the Swedish trial results are representative of the Dutch situation. Until now, the observed mortality in the Netherlands has compared well with the expected mortality predicted by MISCAN if screening takes place, but this is not yet decisive as the expected mortality predicted by MISCAN when there is no screening does not diVer significantly from the observed breast cancer mortality. Furthermore, other factors in addition to screening, such as improvement in treatment, changes in risk factors, and performance of screening, may influence the breast cancer mortality and complicate the comparison between the observed and expected mortality. These factors also aVect assessment of the impact of a screening programme on breast cancer mortality by comparing the observed mortality before and after the introduction of screening. This is illustrated by the mortality reduction reported by Quinn. 2 The observed 12% reduction in breast cancer mortality after seven years of screening was assumed to have been influenced by the widespread adoption of tamoxifen during this period. It is, therefore, unknown to what extent the reduction in mortality was attributable to screening.
We predicted that the reduction in the breast cancer mortality in 1994 induced by the NHS breast screening programme in England and Wales would be 8% in the 55-69 age group. Any additional observed mortality reduction is then due to improvement in the treatment, but random fluctuation may also play a part. Chu et al 3 also reported that their statistical modelling indicated that the recent drop in the breast cancer mortality rate for American white women (6.8% between 1989 and 1993) was too rapid to be explained only by the increased use of mammography.
In 2000 the expected mortality reduction attributable to the NHS breast screening programme in women aged 50-69 is 17%. Accordingly, the current Health of the Nation target of a 25% reduction in the mortality by the year 2000 in the 50-69 age group seems diYcult to achieve with the current screening programme alone-other factors are needed. For the age group 50-64 we expect a maximum mortality reduction of 17% in the long term, which is lower than the estimated mortality reduction of 21% for East Anglia based on interval cancer rates. 14 This difference may reflect the diVerence between the results of the Two County study only, and the five Swedish randomised trials combined, used in the respective studies.
In the Finnish report 4 the eVect on breast cancer mortality attributable to the nationwide screening programme was estimated by comparing the observed breast cancer mortality of the women invited for screening with the breast cancer mortality in women not yet invited. When this method is used, improvement in treatment, changes in risk factors, cohort eVects, and performance of screening do not aVect assessment of the eVects of screening, as these factors can be expected to influence both groups evenly. But the reported reduction in breast cancer mortality was based on small numbers and was not statistically significant. If the comparison between the women screened first and those invited last is repeated after a longer follow up period, when the women invited last have also been screened, the diVerence in breast cancer mortality between these two groups will still represent the diVerence in breast cancer mortality, with and without screening, and the numbers may by then be suYciently large to show a statistically significant reduction. However, the period in which this comparison is possible is also limited, as the diVerence in breast cancer mortality between the two groups will become relatively smaller by increasing numbers of breast cancer deaths in both groups, and, in the long term, will not be distinguishable from random fluctuation.
This method of demonstrating mortality reduction attributable to screening can also be applied to the Dutch nationwide screening programme and the NHS breast screening programme as in these countries, also, the screening programmes were introduced gradually. For the NHS breast screening programme the phased introduction of screening has already been used to compare the survival of patients with cancer in an unscreened population with the survival of those with interval cancers. 15 In conclusion, the eVects of screening on breast cancer mortality are low in the first years after the introduction of screening, and are expected to become apparent around 10 years later. Accordingly, we expected the effect of screening in the Netherlands to be visible only from 1997 onwards and that 70% of the reported 12% mortality reduction in England and Wales in 1994 can be attributed to screening.
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